Fourth Quarter 2023 TMIST Study Updates | February 2024
 
 
 
 
 
130

Number of
Active Sites
96,821

Number of Patients Registered to Date
1

Total New TMIST Sites This Quarter
 
 
Welcome to IN166-Northwest Cancer Center in Valparaiso, IN, the latest site to activate TMIST in the last quarter.
 
 
“Through the dedication of participating trial sites, TMIST enrollment progressed at an impressive pace throughout 2023, reaching more than 95,000 participants by year’s end. This momentum is a testament to the fact that the TMIST study question remains unanswered and that sites are communicating effectively with women in their communities. I ask that practices redouble their efforts with the goal of reaching our 100,000 milestone as quickly as possible in 2024.”

Etta Pisano, MD, FACR
TMIST Study Chair
 
 
Amendment #12
Amendment #12 of the TMIST protocol went into effect Nov. 8, 2023. This amendment includes reference to a new sub-study titled “Short-Term Image-Based Assessment of Breast Cancer Risk for Screening Mammography Utilizing TMIST,” which will utilize existing TMIST data in Appendix IV.

Help Us Increase TMIST Participants
Do you know of any sites interested in offering this trial to constituents, particularly those serving primarily Asian, Native American and Hispanic populations? If so, please forward this newsletter to your colleagues and instruct them to email [email protected] to learn about the study requirements, reimbursement/payment structure and how to start the application process. Deadline for new site activations for TMIST is July 1, 2024.

A Bright Spot in Efforts to Make Clinical Trials More Diverse
Black participation in TMIST continues to stand at about 21% — more than double the average Black participation rate in National Cancer Institute (NCI)-funded clinical trials (9%). In addition, TMIST leaders continue outreach efforts to assemble a diverse cancer screening trial population. Even as screening mammography volumes remain below pre-pandemic levels, TMIST enrollment soared past 80,000.

Reminder: TMIST Outreach Materials
In case you missed it, a variety of news stories about the trial, along with educational and recruitment materials, are posted on the ECOG-ACRIN website. Please check this website regularly for new materials and updates to existing resources. Also, please share these resources widely with potential enrollees, cancer research advocates and others in your community.

Blood and Buccal Collection Reminder
TMIST sites must collect blood and buccal samples from women who consent to provide them — as soon as possible after enrolling participants in TMIST, ideally at T0 — and develop a site plan for collection, processing and storing samples (prior login to your Cancer Therapy Evaluation Program (CTEP) — Identity and Access Management (IAM) account is required). Note the new deadline for blood and buccal sample collection introduced for participants enrolled under (and subsequent to) Amendment #9. The sample collection deadline remains the same for TMIST participants enrolled prior to Amendment #9 (i.e., no later than the T4 screening visit time point).
 
 
Physics QC Program
Compliance with the TMIST Physics Quality Control (QC) Program is now easier for U.S. sites that have complied with the TMIST QC for at least one year. If your site qualifies, you will no longer have to perform weekly, monthly or annual TMIST-specific QC on your TMIST-credentialed mammography systems. The TMIST Physics QC Team has notified sites that currently qualify. If you think your site qualifies but you have not received notification, email [email protected].

COVID-19 Vaccinations and Mammography
Some patients who receive COVID-19 vaccinations may temporarily develop benign swollen lymph nodes, which can show up on mammograms and other imaging tests. Please document the timing of each COVID-19 vaccination on visit forms, if not previously reported in Rave (login required).

Site Responsibilities for TMIST After Closing New Accruals
If your institution decides to close EA1151 to prospective enrollment, please remember your institution is still responsible for the following:
  1. Continuing to manage all protocol assessments for subjects previously enrolled.
  2. Maintaining IRB approval — whether NCI CIRB for U.S.-based sites or local IRB for international sites — of EA1151 throughout the entire protocol life cycle.
  3. Meeting all future data submission requirements for subjects previously enrolled.
  4. Submitting tissue, blood and buccal samples for women who consented.
  5. Addressing any data management, central monitoring or audit queries.
These responsibilities remain with the enrolling institution until the study is added to the ECOG-ACRIN list of studies no longer requiring additional activities, or if all subjects are transferred to another site.

Full Study Closeout Requirements
Please note that full study closeout cannot occur at a site unless the following requirements are met:
  1. Study has met its accrual goal or is closed for accrual at the Signatory Institution as well as at all Component and/or Affiliate Institutions relying on the Signatory Institution for this study.
  2. All study participants have completed study interventions and follow-up activities — or — no study participants were enrolled.
  3. No further research activity exists for this study (including recruitment, enrollment, data collection, data analysis and data submission).
Submit Pathology Materials After Breast Biopsy/Surgery
Please submit pathology reports, diagnostic pathology slides and tissue from breast biopsies/surgeries to the ECOG-ACRIN Central Biorepository and Pathology Facility as soon as your pathology department releases the materials. Access instructions on the EA1151 documents portal page (CTEP IAM account required).

Remote Consent Still Allowed for TMIST
Changes were made to section 2.3.8 of the CIRB Standard Operating Procedures (SOPs) to permit the use of remote consent outside of the COVID-19 public health emergency. These changes are summarized in the Summary of Changes to the SOPs. Please contact the NCI CIRB Help Desk via email at [email protected] with any questions.

 
 
Top Accruing Sites — Q4 2023
 
U.S. NCORP Sites*
 
  1. Women’s Diagnostic Center — Munster (Dr. Kendrith Rowland, PI)

  2. University Medical Center — New Orleans (Dr. Mignonne Morrell, PI)

  3. Spartanburg Medical Center/Gibbs Cancer Center and Research Institute (Dr. Amarinthia Curtis, PI)

International Sites*
  1. CERIM: Centro de Estudios Radiologicos Integrales de la Mamarios (Dr. Daniel Lehrer, PI)

  2. Oncosalud S.A.C. (Dr. Pilar Montenegro, PI)

  3. Odette Cancer Centre — Sunnybrook Health Sciences Centre (Dr. Roberta Jung, PI)
U.S. LAPS Sites*
 
  1. University of North Carolina at Chapel Hill (Dr. Cherie Kuzmiak, PI)

  2. University of North Carolina-Hillsborough Campus (Dr. Cherie Kuzmiak, PI)

  3. Wayne State University/Karmanos Clinic (Dr. Alit Jeannie Yousif, PI)
U.S. Main Member Sites*+
 
  1. Zuckerberg San Francisco General Hospital and Trauma Center (Dr. Rita Fremanis, PI)

  2. University of Cincinnati Cancer Center/UC Medical Center (Dr. Lawrence Sobel, PI)

  3. University of Virginia Cancer Center (Dr. Matthew Miller, PI)
 
*Denotes individual sites – not networks
+Includes freestanding and private practice radiology sites
 
 
london
 
new_york
 
View Online

Opt out from TMIST e-newsletter

American College of Radiology
1892 Preston White Drive | Reston, VA 20191 | 800-227-5463

Copyright © 2024 American College of Radiology. All Rights Reserved.